The Science and Medicine of VTE Prophylaxis

Part 2: Dynamic DVT Risk Assessment During Hospital Admission—Focus on Prophylaxis Triggers and Optimal Use of LMWHs

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

February 15, 2009

Expiration Date:

February 15, 2011

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: cardiologists, emergency physicians, interventional cardiologists, hospitalists, internal medicine specialists, thrombosis experts, oncologists, surgeons, orthopedic surgeons, geriatricians, critical care experts, pulmonary medicine experts, hematologists, and hospital pharmacists.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported by an independent medical educational grant from sanofi-aventis U.S. Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Samuel Z. Goldhaber, MD
Professor of Medicine, Cardiovascular Division
Harvard Medical School
Director, Venous Thromboembolism Research Group
Brigham and Women’s Hospital
President, North American Thrombosis Forum
Boston, Massachusetts

Faculty Disclosures:

Samuel Z. Goldhaber, MD, discloses that he has received funding for clinical research from sanofi-aventis, Eisai, Boehringer-Ingelheim, and Bristol-Myers Squibb. He has also served as a consultant for sanofi-aventis, Eisai, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Pfizer, Possis, Medscape, and Duramed.

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

• Learn how to apply current guidelines issued by national professional organizations and in patients at risk for DVT with medical and surgical conditions.
• Learn how to assess and risk stratify patients across the comprehensive medical and surgical disease state spectrum and evaluate their risk for VTE upon the initial hospitalization phase.
• Learn how to perform dynamic risk assessment and risk stratify patients who already are hospitalized but who are not receiving DVT prophylaxis, but who, based on risk across the comprehensive medical and surgical disease state spectrum, may require DVT prophylaxis.
• Learn how to risk stratify patients who are preparing for hospital discharge and ensure that appropriate patients continue to receive the appropriate duration of pharmacologic prophylaxis following hospital discharge, whether it be to a skilled nursing facility, home, or rehabilitation environment.
• Learn to risk stratify medical, oncology, and surgical patients, assess their likelihood for incurring DVT, and be aware of prophylaxis measures that can reduce the incidence of DVT in these patient populations.
• Learn to assess and manage special needs of surgical, cancer, and orthopedic patients at risk for DVT, with a focus on protecting against recurrent DVT in patients undergoing surgery, and assessing need for prolonged duration of thromboprophyaxis.
• Learn how to apply landmark clinical trials focusing on DVT prevention in medical and surgical patients to their clinical practice.
• Learn how to evaluate, select among, and appropriately use the range of pharmacologic options available for DVT prophylaxis, including warfarin, unfractionated heparin, and LMWHs.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved